The Boehringer Ingelheim group, headquartered in Ingelheim, Germany, is dedicated to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. We operate in nearly 50 countries and employ more than 44 000 people worldwide. More than 7500 scientists work in multidisciplinary teams within our global R&D network in six large therapeutic areas, including virology.
Boehringer Ingelheim has a longstanding commitment to virology, including developing innovative therapies for HIV/AIDS and HCV. Through pioneering science, Boehringer Ingelheim strives to spread the cure in HCV and ease the burden of the disease. Boehringer Ingelheim’s clinical research team is working with experts from all over the world to extend a cure to more patients suffering from HCV, including those difficult to cure. Boehringer Ingelheim is investigating BI 201335 and BI 207127 through HCVersoTM, our rigorous clinical trial programme that is designed to find answers to the challenges that patients with HCV face.